China Medical System Holdings Limited (SGX:8A8)
Singapore · Delayed Price · Currency is SGD | Market Cap | 5.03B +67.6% |
| Revenue (ttm) | 1.51B +9.9% |
| Net Income | 273.80M -8.1% |
| EPS | 0.11 -7.8% |
| Shares Out | n/a |
| PE Ratio | 18.39 |
| Forward PE | 13.39 |
| Dividend | 0.05 (2.45%) |
| Ex-Dividend Date | Apr 28, 2026 |
| Volume | 21,500 |
| Average Volume | 4,145 |
| Open | 2.100 |
| Previous Close | 2.160 |
| Day's Range | 2.100 - 2.100 |
| 52-Week Range | 2.050 - 2.550 |
| Beta | n/a |
| RSI | 37.05 |
| Earnings Date | May 18, 2026 |
About SGX:8A8
China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republic of China. The company offers cardio-cerebrovascular products include VELPHORO, a sucroferric oxyhydroxide chewable tablets and diazepam nasal spray for seizure clusters; XinHuoSu, a recombinant human brain natriuretic peptide for acute heart failure; Plendil, a felodipine sustained release tablets for hypertension; and Deanxit, a flupentixol and melitracen tablets for mild-to-moderate ... [Read more]
Financial Performance
In 2025, SGX:8A8's revenue was 8.21 billion, an increase of 9.95% compared to the previous year's 7.47 billion. Earnings were 1.49 billion, a decrease of -8.08%.
Financial numbers in CNY Financial StatementsNews
CMS (867.HK/8A8.SG): Innovative Drug Oral JAK1 Inhibitor Povorcitinib Has Been Included in the List of Breakthrough Therapeutic Drugs in China
SHENZHEN, CHINA, Dec. 15, 2025 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS”, or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an i...
CMS (867.HK; 8A8.SG) Signed A Distribution Agreement for Ophthalmic Drugs Lucentis® and Beovu®
SHENZHEN, CHINA, Oct. 27, 2025 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 27 October 2025, the Group through its subsidiary CMS VI...